In an increasingly interconnected world, where patient travel for specialized treatments and wellness tourism is on the rise, the robustness of a nation’s medical device regulation becomes a paramount indicator of its commitment to quality of care. Against this backdrop, the World Health Organization (WHO) recently made a significant announcement, confirming that Singapore’s Health Sciences Authority (HSA) has attained the highest possible classification for medical device regulatory performance under the organization’s comprehensive global benchmarking framework.
Singapore’s Regulatory Zenith: A Global First
Following a meticulous evaluation utilizing the WHO’s Global Benchmarking Tool Plus for medical devices (GBT+MD), the HSA was awarded Maturity Level 4 (ML4). This designation represents the pinnacle of regulatory achievement within the WHO’s system for national authorities overseeing medical products. Singapore stands as the inaugural WHO Member State to achieve this distinguished level specifically for medical device regulation. From an industry perspective, this accomplishment is not merely a bureaucratic milestone; it fundamentally solidifies Singapore’s reputation as a leading global healthcare destination, bolstering confidence for international patients seeking advanced medical care.
This esteemed classification unequivocally affirms that Singapore’s regulatory infrastructure operates at an exceptionally advanced performance level, incorporating robust mechanisms for continuous enhancement. Crucially, it signifies a consistent assurance of the safety, quality, and performance of medical devices throughout their entire lifecycle. This comprehensive oversight spans from initial market authorization and rigorous clinical evaluation to vigilant post-market surveillance. For those considering cross-border healthcare, such a stringent and proven regulatory environment offers unparalleled peace of mind regarding the devices and technologies used in their treatment.
Singapore is already recognized as a significant global epicenter for medical technology innovation, boasting approximately 200 manufacturers. These companies produce a diverse array of devices, ranging from sophisticated in vitro diagnostics to cutting-edge software as a medical device. This regulatory achievement, therefore, not only validates the quality of these locally produced innovations but also enhances Singapore’s appeal to international patients as a healthcare destination that prioritizes both innovation and safety.
Ensuring Unparalleled Patient Safety and Innovation
Emphasizing the foundational importance of effective regulation, Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data, commented on Singapore’s achievement. “Effective regulation is essential to ensure that health products, including medical devices, reaching patients are safe, effective and of assured quality,” she stated. Dr. Nakatani further highlighted, “Singapore’s achievement reflects an exceptional commitment to regulatory excellence and demonstrates how sustained investment in regulatory capacity can protect populations, support innovation and strengthen trust in medical technologies. It also provides an important reference point for other countries working to strengthen their own regulatory systems and ensure access to safe and quality-assured health products and technologies.” This perspective underscores the broader impact of Singapore’s regulatory prowess, establishing a benchmark that can guide other nations striving to enhance their own healthcare standards, especially as global healthcare and medical tourism continue to expand.
Globally, the capacity of regulatory bodies remains notably disparate. A concerning statistic reveals that only 32% of regulatory authorities worldwide possess the full capability to ensure that medicines, vaccines, and other health products consistently meet the requisite standards for safety, quality, and effectiveness. The WHO’s benchmarking initiatives are therefore vital, serving to pinpoint areas where improvements are needed to foster stable, well-functioning, and integrated regulatory systems across its Member States. In our editorial view, Singapore’s success offers a tangible roadmap, demonstrating that with strategic investment and commitment, a nation can not only safeguard its own population but also contribute significantly to global health security and the integrity of international patient care.
A Beacon for Global Regulatory Harmonization
This rigorous benchmarking assessment was carried out in February 2026 by a distinguished panel of international experts, working in collaboration with WHO personnel from both headquarters and the WHO Regional Office for the Western Pacific. The comprehensive process encompassed a thorough review of extensive evidence submitted by the HSA, complemented by in-depth technical discussions with the teams responsible for regulatory oversight. This meticulous approach ensures that the ML4 designation is not merely symbolic but reflects an exhaustive and objective evaluation of HSA’s operational excellence.
Expressing profound gratitude and pride in this global recognition, Adjunct Professor (Dr) Raymond Chua, Chief Executive Officer of the Health Sciences Authority, Singapore, shared his perspective. “It is a great honor for Singapore’s Health Sciences Authority to be recognized at the highest WHO Maturity Level (ML4) classification for medical device regulation,” he affirmed. He further elaborated, “Together with our ML4 status for medicines and as a Stringent Regulatory Authority for high-risk in-vitro diagnostics, this milestone reflects HSA’s sustained effort to build a robust and forward-looking regulatory system that safeguards patients while enabling timely access to innovative health products. HSA will continue to collaborate closely with WHO and partners to share experience and support regulatory capacity building across the Region, whilst at the same time work with regulators to establish HSA as a global reference point that they can confidently rely on for the evaluation of their products”. This statement highlights HSA’s dual commitment: protecting patients and fostering innovation, while also positioning Singapore as a trusted reference point for other national regulatory bodies. For the discerning international patient, this translates into an assurance of receiving care within a system that is not only self-regulating at the highest standard but also actively contributes to elevating global quality of care.
A Track Record of Excellence and Leadership
This latest achievement builds upon a strong foundation of regulatory excellence. Singapore had previously attained the WHO’s highest maturity level for the regulation of medicines and imported vaccines in 2022. Regulatory authorities that reach ML4 may subsequently qualify as a WHO Listed Authority (WLA) following additional performance assessments. This WLA designation recognizes health regulators capable of serving as reference authorities for other countries when making critical decisions about approving medical products. The HSA was designated as a WLA for medicines in 2023 and further listed in 2024 for an expanded scope, encompassing all regulatory functions pertinent to the medicines product stream. This consistent track record of achieving and maintaining the highest global standards significantly enhances Singapore’s appeal as a trusted healthcare destination, attracting international patients and fostering robust cross-border healthcare collaborations.
The HSA actively engages in efforts to harmonize international regulatory standards, demonstrating its leadership on a global stage. This includes its participation in key bodies such as the International Medical Device Regulators Forum (IMDRF) and the Medical Device Single Audit Program (MDSAP), alongside various regional initiatives. In its role as Chair of the IMDRF Management Committee in 2026, the regulatory authority is strategically positioned to drive global regulatory alignment for rapidly emerging technologies. This encompasses innovations like digital health solutions, artificial intelligence, and personalized medical devices, all of which are increasingly vital in the realm of global healthcare and patient travel. This proactive engagement ensures that Singapore remains at the forefront of regulatory evolution, directly benefiting the quality of care available to both domestic and international patients.
Understanding the WHO’s Rigorous Benchmarking Framework
The WHO Global Benchmarking Tool Plus for medical devices (GBT+MD) is an advanced extension of the original WHO Global Benchmarking Tool (GBT). It is specifically engineered to assess and fortify national regulatory systems for medical devices. While it adheres to core regulatory principles common to other medical products such as medicines and vaccines, the GBT+MD is uniquely tailored to address the distinct and complex challenges inherent in regulating medical technologies. The framework meticulously evaluates regulatory authorities against an extensive set of over 260 indicators, covering a broad spectrum of critical functions:
- Regulatory Systems: Examination of the overall structure and governance of the regulatory framework.
- Product Registration and Market Authorization: Assessment of processes for approving and listing medical devices.
- Laboratory Testing: Evaluation of capabilities for independent testing and verification of device quality.
- Post-Market Surveillance: Scrutiny of systems for monitoring device safety and performance once on the market.
- Clinical Trials Oversight: Review of ethical and scientific rigor in the supervision of clinical investigations.
- Regulatory Inspections and Licensing of Establishments: Assessment of inspection protocols and licensing requirements for manufacturers and distributors.
This comprehensive assessment process is designed to determine both the maturity and operational functionality of national regulatory systems, providing a clear pathway for their continuous improvement and ultimately enhancing global healthcare standards.
Bottom Line: Implications for Global Healthcare and Medical Tourism
Singapore’s achievement of WHO Maturity Level 4 for medical device regulation marks a pivotal moment, with profound implications for the global healthcare landscape and the burgeoning medical tourism sector. Key takeaways include:
- Elevated Trust for International Patients: This highest regulatory classification offers an unparalleled assurance of safety and quality for international patients considering Singapore for their medical needs, solidifying its position as a premier healthcare destination.
- Reinforced Innovation Hub Status: The ML4 designation not only validates Singapore’s existing medical technology innovation but also creates an attractive environment for further investment and development, benefiting the range of treatments available for patient travel.
- Global Reference Point: Singapore’s HSA now serves as a significant benchmark and reference authority, guiding other nations in strengthening their own regulatory systems and promoting a higher standard of global healthcare.
- Leadership in Future Technologies: Through its active role in international harmonization and chairmanship of the IMDRF, Singapore is poised to shape the future of medical device regulation, particularly for emerging digital health and AI solutions, ensuring these advancements contribute safely to international patient care and wellness tourism.
This regulatory milestone underscores Singapore’s unwavering commitment to excellence, positioning it as a leading light in the global pursuit of superior quality of care and patient safety in cross-border healthcare.
The news signal for this article was referred from: https://www.who.int/news/item/10-03-2026-singapore-sets-global-first-by-reaching-who-s-highest-classification-for-medical-device-regulation